Lung & Respiratory Health Update: IPF, COPD, Asthma & More

This week in lung and respiratory health: PureTech highlights gaps in IPF diagnosis and support, urging holistic care. Apogee’s APG808 shows promise in asthma, reducing FeNO by 53%. Rein’s Phase 2 RENEW trial for LTI-03 targets IPF. Beam’s BEAM-302 gene therapy for AATD receives FDA RMAT designation. AstraZeneca’s Trixeo Aerosphere inhaler reduces climate impact by 99.9%. Connect Biopharma’s Seabreeze STAT study evaluates rademikibart for acute asthma exacerbations. Dupixent gains approval in Singapore for COPD, offering significant reductions in exacerbations and improvements in lung function.

Видео Lung & Respiratory Health Update: IPF, COPD, Asthma & More канала LucidQuest